SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001829126-24-002193
Filing Date
2024-04-03
Accepted
2024-04-03 17:08:38
Documents
17
Period of Report
2024-04-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 57618
2 EXHIBIT 10.1 titanpharma_ex10-1.htm EX-10.1 27800
3 EXHIBIT 10.2 titanpharma_ex10-2.htm EX-10.2 16287
4 EXHIBIT 10.3 titanpharma_ex10-3.htm EX-10.3 24953
5 EXHIBIT 10.4 titanpharma_ex10-4.htm EX-10.4 22207
  Complete submission text file 0001829126-24-002193.txt   350363

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ttnp-20240402.xsd EX-101.SCH 2991
7 XBRL LABEL FILE ttnp-20240402_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE ttnp-20240402_pre.xml EX-101.PRE 22343
20 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3702
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 24819910
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)